InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 30 November 2023

This study is evaluating a new immunotherapy in people with relapsed/refractory multiple myeloma and relapsed/refractory light chain amyloidosisFirst-in-human, Open-label Phase 1/2 Study to Investigate Safety and Efficacy of SAR445514, an NKcell Engager (NKCE) Targeting B-cell Maturation Antigen (BCMA) in Monotherapy in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and in Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

Clinical summary

Summary

This study will comprise of 3 parts.

Part 1 - Dose Escalation

Part 1a will evaluate several doses of the study drug (called SAR445514) in people with relapsed/refractory (RR) multiple myeloma (MM) to determine 2 doses that will be tested in the dose optimisation part.

 

Part 1b will begin sequentially after Part 1a, and will evaluate these 2 doses in people with RR light chain amyloidosis (LCA) to ensure these doses are also safe for RRLCA participants.

Part 2 - Dose Optimisation

This part will be evaluating 2 doses determined from Part 1 to determine the preliminary recommended Phase 2 Dose (pRP2D) and schedule for SAR445514 in people with RRMM.

Part 3 - Dose Expansion

This part will evaluate the preliminary efficacy of the confirmed RP2D and schedule for SAR445514 in people with RRMM (Part 3a) and RRLCA (Part 3b).

Conditions

This trial is treating patients with relapsed/refractory multiple myeloma and light chain amyloidosis

Cancer

Blood Cancers Haematological

Age

People18+

Phase

I/II

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

  • NCT05839626
  • TCD17710; U1111-1279-2985; 2022-502057-33-00

Trial sponsor

Sanofi

Scientific Title

First-in-human, Open-label Phase 1/2 Study to Investigate Safety and Efficacy of SAR445514, an NKcell Engager (NKCE) Targeting B-cell Maturation Antigen (BCMA) in Monotherapy in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and in Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

Eligibility

Inclusion

  • Participants must have a documented diagnosis of multiple myeloma (Part 1a, 2, and 3a) or light chain amyloidosis (Part 1b and 3b)
  • Participants with RRMM (Part 1, 2a, and 3a)
  • Participants with measurable disease for RRMM
  • Participants with MM must have received at least 2 prior lines of therapy which must include at least 2 consecutive cycles of a second or third generation immunomodulator, steroid, proteasome inhibitor and anti-CD38 monoclonal antibody (MoAb).
  • Participants must have documented evidence of progressive disease (PD), as per IMWG 2016 criteria.
  • Participants with RR LCA (Part 1b and 3b) must have received at least 1 prior line of treatment comprising at least 1 proteasome inhibitor.
  • Participants with measurable disease according to ISA 2012
  • Participants must have documented evidence of progressive disease (PD), as per ISA 2012 criteria.
  • One or more organ impacted by amyloidosis as per National comprehensive cancer network (NCCN) guidelines.
  • For dose escalation, body weight within 40 to 120 kg
  • Capable of giving signed informed consent

Exclusion

  • Primary refractory MM defined as participants who never achieved at least a minimal response with any treatment during the disease course.
  • Second primary malignancy
  • Participants with RRMM (Part 1a, 2a, and 3a)

    1. For MM participants, primary systemic LCA and plasma cell leukemia
    2. For MM participants, congestive heart failure (New York Heart Association [NYHA]) Grade ≥II; cardiomyopathy, active ischemia, or any other uncontrolled cardiac condition
  • Participants with RR LCA (Part 1b and 3b)

    1. For LCA participants, evidence of clinically significant cardiovascular condition, defined as one or more of the following:
    2. N-terminal prohormone of brain natriuretic peptide (NT-proBNP) >8500 ng/mL
    3. New York Heart Association (NYHA) classification IIIb or IV heart failure
    4. Heart failure that, in the opinion of the Investigator, is not primarily related to LCA cardiomyopathy (including, but not limited to, ischemic heart disease, uncorrected valvular disease, infections)
    5. Prior event (history) in the last 6 months of acute coronary syndrome, myocardial infarction or unstable angina as well as participants who during the last 6 months experienced a percutaneous cardiac intervention with stent and/or a coronary artery bypass
    6. Hospitalization in the last 4 weeks prior to treatment related to a cardiovascular event
    7. Participants with prior history of arrhythmia and/or cardiac conduction disorders for which a pacemaker or an implantable cardioverter defibrillator (ICD) is required but has not been placed. This includes, but may not be limited to, sustained ventricular tachycardia, association of an atrioventricular, or sinoatrial nodal dysfunction
    8. For LCA participants, a systolic blood pressure <100 mmHg or a diastolic blood pressure <55 mmHg
    9. For LCA participants: previous or current diagnosis of symptomatic MM, including the presence of lytic bone disease, plasmacytomas, ≥60% plasma cells in the BM, or hypercalcemia
  • All participants

    1. Uncontrolled infection within 14 days prior to study treatment
    2. Known acquired immunodeficiency syndrome-related illness or known human immunodeficiency virus (HIV) disease requiring antiviral treatment or active hepatitis A (defined as positive hepatitis A antigen or positive IgM); HIV serology at screening will be tested for participants in countries where it is required by local regulations
    3. Uncontrolled or active hepatitis B virus (HBV) infection: participants with positive B surface antigen (HBsAg) and/or HBV deoxyribonucleic acid (DNA)
    4. Active hepatitis C virus (HCV) infection: positive HCV ribonucleic acid (RNA) and negative anti-HCV
  • Any anti-MM drug treatment within 14 days before study treatment
  • Prior allogenic hematopoietic stem cell (HSC) transplant with active graft-versus-host disease (GvHD) (GvHD any grade and/or being under immunosuppressive treatment within the last 2 months prior to randomization)
  • Any major procedure within 14 days before the initiation of the study treatment
  • Administration of an anti-CD38 monoclonal antibody (isatuximab or daratumumab) less than 90 days prior to the first administration of study treatment
  • Administration of an anti-BCMA agent (including, but not limited to, CAR T-cells, TCEs, antibody drug conjugate) less than 21 days prior to the administration of study treatment
  • Unresolved toxicities from prior anticancer therapy, defined as not having resolved to CTCAE Version 5.0 Grade 1.
  • Participants with a contraindication to dexamethasone
  • Received any other investigational drugs or prohibited therapy for this study within 28 days or 5 half-lives from study treatment, whichever is shorter
  • Hemoglobin <8 g/dL (5.0 mmol/L)
  • Platelets <50 × 10^9/L (not permissible to transfuse a participant within 1 weeks prior to the screening platelet count to reach this level)
  • Absolute neutrophil count (ANC) <1000 μL (1 × 10^9/L)
  • Creatinine clearance <30 mL/min (Modification of Diet in Renal Disease Formula)
  • Total bilirubin >1.5 × upper limit of normal (ULN) (unless the subject has documented Gilbert syndrome in which case direct bilirubin should not be >2.5 × ULN)
  • Aspartate aminotransferase (AST/SGOT) or Alanine aminotransferase (ALT/SGPT) >2.5 × ULN
  • Patients with Grade 3 or 4 hypercalcemia (corrected serum calcium of >12.5 mg/dL; >3.1 mmol/L; ionized calcium >1.6 mmol/L; or requiring hospitalization) will not be eligible unless patients recover to Grade 2 or less under anti-hypercalcemia treatment.
  • Individuals accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalized
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial

Inclusion

  • You have had a certain type of treatment or surgical procedure.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.